E-GEOD-2251 - Transcription profiling of human breast cancer cells expressing ERalpha and treated with 17beta-estradiol

Submitted on 7 February 2005, released on 25 August 2007, last updated on 27 March 2012
Homo sapiens
Samples (12)
Array (1)
Gene expression changes caused by estrogen treatment of breast cancer cells that re-express ERalpha was investigated by infecting ER-negative MDA-MB-231 breast cancer cells for 24 h with recombinant adenovirus encoding full-length human ERalpha (Ad-ERalpha) or control vector (Ad-LacZ), and treating them with 0·01% ethanol (vehicle control) or 10-8 M 17beta-estradiol (E2). After 48 h of treatment, total RNA was isolated and used for transcript profiling on Affymetrix GeneChips. Three independent biological replicates of this experiment were carried out.
Experiment types
transcription profiling by array, co-expression, compound treatment, genetic modification
Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. J G Moggs, T C Murphy, F L Lim, D J Moore, R Stuckey, K Antrobus, I Kimber, G Orphanides. J Mol Endocrinol 34(2):535-51 (2005)
Investigation descriptionE-GEOD-2251.idf.txt
Sample and data relationshipE-GEOD-2251.sdrf.txt
Processed data (1)E-GEOD-2251.processed.1.zip
Array designA-AFFY-33.adf.txt